Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the most established and
commonly used cellular immunotherapy in cancer care. It is the most potent anti-leukemic …

Graft-versus-host disease (GVHD) represents the most serious and challenging
complication of allogeneic haematopoietic stem-cell transplantation (HSCT). New insights …

Background Chronic graft-versus-host disease (GVHD) is the leading cause of later illness
and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that …

Background In chronic granulomatous disease allogeneic haemopoietic stem-cell
transplantation (HSCT) in adolescents and young adults and patients with high-risk disease …

The success of reduced intensity conditioning (RIC) transplantation is largely dependent on
alloimmune effects. It is critical to determine whether immune modulation with anti–T-cell …

The most common cause of post-transplant mortality in patients with hematological
malignancy is relapse, followed by GvHD, infections, organ toxicity and second malignancy …

Hematopoietic stem cell transplantation (HSCT) has been used as a curative standard of
care for moderate to severe primary immunodeficiency disorders as well as relapsed …

Understanding inter-subject variability in drug pharmacokinetics and pharmacodynamics is
important to ensure that all patients attain suitable drug exposure to achieve efficacy and …

Reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT)
with alemtuzumab, fludarabine, and melphalan is an effective approach for patients with …

Improving haematopoietic cell transplantation outcomes by selection of an HLA-matched
unrelated donor is best practice; however, donor selection by secondary characteristics is …